FoxO1 is required for high glucose-dependent cardiac fibroblasts into myofibroblast phenoconversion
Cellular Signalling, 2021In the normal heart, cardiac fibroblasts (CFs) maintain extracellular matrix (ECM) homeostasis, whereas in pathological conditions, such as diabetes mellitus (DM), CFs converse into cardiac myofibroblasts (CMFs) and this CFs phenoconversion increase the synthesis and secretion of ECM proteins, promoting cardiac fibrosis and heart dysfunction.
Raúl Vivar +2 more
exaly +3 more sources
Phenocopy and Phenoconversion: Do they Complicate Association Studies?
Pharmacogenomics, 2012Current pharmacogenetic focus on genotype A number of clinically relevant drug metabo lizing enzymes (DMEs) are expressed poly morphically in the population, giving rise to at least three distinct genotypes; extensive metabolizers (EMs), poor metabolizers (PMs) and intermediate metabolizers.
Rashmi R, Shah, Robert L, Smith
openaire +2 more sources
Mechanical regulation of myofibroblast phenoconversion and collagen contraction
Experimental Cell Research, 2019Activated fibroblasts promote physiological wound repair following tissue injury. However, dysregulation of fibroblast activation contributes to the development of fibrosis by enhanced production and contraction of collagen-rich extracellular matrix.
Boris, Hinz +2 more
openaire +2 more sources
The Importance of Phenoconversion when using the CYP2D6 Genotype in Clinical Practice
Pharmacogenomics, 2022Tweetable abstract Clinical phenoconversion needs to be incorporated when interpreting and applying CYP2D6 results in clinical care. This article describes how this can be performed either manually or by utilizing online tools and resources. #Phenoconversion #Pharmacogenomics.
Emily J Cicali, Kristin Wiisanen
openaire +2 more sources
Pharmacogenetic guided drug therapy – how to deal with phenoconversion in polypharmacy
Expert Opinion on Drug Metabolism and ToxicologyThe prevalence of polypharmacy and the increasing availability of pharmacogenetic information in clinical practice have raised the prospect of data-driven clinical decision-making when addressing the issues of drug-drug interactions and genetic polymorphisms in metabolizing enzymes.
Julia C Stingl, Roberto Viviani
exaly +3 more sources
I01 Unawareness of motor phenoconversion in huntington disease
Journal of Neurology, Neurosurgery & Psychiatry, 2012Background Unawareness of disease manifestations in neurodegenerative diseases has been defined by Flashman et al 2002 as “pathological unawareness of a neurological or functional deficit” and by Antoine et al 2004 as “the discrepancy between the patient9s self report and the report of a natural caregiver or the clinical rating of a health ...
E McCusker +8 more
openaire +1 more source
The Role of Phenoconversion in the Pharmacogenetics of Psychiatric Medication
Pharmacogenomics, 2023Martina Hahn, Sibylle C Roll
openaire +2 more sources
ObjectiveTo evaluate neurofilament light (NfL) as a biomarker of the presymptomatic phase of amyotrophic lateral sclerosis (ALS).MethodsThe study population includes 84 individuals at risk for developing ALS, 34 controls, 17 ALS patients, and 10 phenoconverters (at‐risk individuals observed both before and after the emergence of clinically manifest ...
Benatar, M +4 more
openaire +3 more sources
Predicting Phenoconversion in Pure Autonomic Failure (4258)
Neurology, 2020Elizabeth Coon +6 more
openaire +1 more source
The Importance of Phenoconversion when using the CYP2D6 Genotype in Clinical Practice
Pharmacogenomics, 2022Emily J Cicali, Kristin Wiisanen
exaly